Latest Conference Articles

Elizabeth Ofili, MD, discusses the importance of annual meetings, such as HFSA 2019, for outreach and engaging patient populations about heart failure.

At the annual meeting dedicated to heart failure, investigators present nutritional recommendations for patients, which includes dietary consultations, bariatric surgery, and a reduction in saturated fats and sodium.

Shaquille O'Neal, Ed.D, and Elizabeth Ofili, MD, discuss using unconventional mediums to engage non-patients and spread awarness of heart failure — specifically in African Americans.

A proof of concept trial examining spironolactone for heart failure prevention presented at HFSA 2019 found spironolactone use did reduce PIIINP or that its impact on PIIINP was mitigated by galectin-3.

There are many options to treat heart failure for patients suffering from end stage kidney disease.

Results of the AMBER study, presented at HFSA 2019, found that patiromer can help improve spironolactone use while also reducing the prevalence of hyperkalemia.

While the benefits are clear, there are still some hurdles that remain preventing an increase in suggested dialysis frequency.

What was learned from the newest data for sacubitril/valsartan for HFrEF?

A study presented at HFSA 2019 Scientific Sessions found that virtual visits were a feasible option that could reduce no-show rates among heart failure patients following hospitalization.

Investigators present data during the HFSA meeting on how different types of meals at different time impact the body’s circadian rhythm.

Emerging mechanical therapy options have given life to a field which has gone under severe recharacterization in an era of increased obesity.

Hospital costs, length of stay, and even mortality were shown to be significantly cut in TAVR patients with comorbid heart failrue than those without, new data shows.

By doubling the recommended weekly dialysis, patients see a number of benefits, including a reduction in blood pressure and improvements in cardiovascular vibration.

The headline drug class has been quickly added to cardiologists' toolsets, amid more and more phase 3 data.

Despite an embrace of greater patient populations by the FDA, cardiovascular research into stem cell therapy has been slow and burdened.

A six-month regimen of the oral therapy showed patients with out-of-proportion PH improved their six-minute walking test scores.

How do a pair of burgeoning agents influence endocrinology and renal outcomes in cardiovascular care?

In a presentation at the annual HFSA meeting, investigators compare the level of care and ultimate outcomes treating heart failure patients for cardiologists and non-cardiologists.

As safety and efficacy programs advance, clinicians consider the investigative therapy's potential in cardiology.

At the annual HFSA meeting, investigators explain how obstructed sleep apnea and central sleep apnea drive cardiovascular disease.

A new study shows just more than 55% of all heart failure-based trials on ClinicalTrials.gov have shared results since 2008.

Investigators report findings no significant associations between BP control and cardiovascular mortality in patients from differing race/ethnicities with HF, stratified by hypertension treatment.

A post hoc analysis of TOPCAT shows older patients with HFpEF report consistent efficacy with spironolactone, but worsening safety outcomes.

Prior to the start of HFSA, Dr. Murray dives through how the extensive history of heart failure research has lead to today's greatest cardiovascular breakthroughs.

A former D.C. healthcare attorney and founder of the Macular Degeneration Association discusses legal problems faced by retina specialists when providing care to their patients with AMD.

Chirag Jhaveri, MD, took part in a Q&A about the results of the phase 3 HAWK and HARRIER studies examining brolucizumab for treatment of nAMD.

Results of a study from investigators at the Retina Center of Minnesota found that same-day injections were preferred by more than 97% of patients.

Manjot Gill, MD, discusses the results of her study which found early diagnosis and treatment of neovascular age-related macular degeneration could help save a patient’s vision.